Analysis of deaths in patients awaiting heart transplantation: impact on patient selection criteria.

G. A. Haywood, P. R. Rickenbacher, P. T. Trindade, L. Gullestad, J. P. Jiang, J. S. Schroeder, R. Vagelos, P. Oyer, M. B. Fowler

Division of Cardiovascular Medicine and Surgery, Stanford University School of Medicine, California 94305-5246, USA.

OBJECTIVE: To analyse the clinical characteristics of patients who died on the Stanford heart transplant waiting list and to develop a method for risk stratifying status 2 patients (outpatients). METHODS: Data were reviewed from all patients over 18 years, excluding retransplants, who were accepted for heart transplantation over an eight year period from 1986 to 1994. RESULTS: 548 patients were accepted for heart transplantation; 53 died on the waiting list, and 52 survived on the waiting list for over one year. On multivariate analysis only peak oxygen consumption (peak VO2: 11.7 (SD 2.7) v 15.1 (5.2) ml/kg/min, P = 0.02) and cardiac output (3.97 (1.03) v 4.79 (1.06) litres/min, P = 0.04) were found to be independent prognostic risk factors. Peak VO2 and cardiac index (CI) were then analysed in the last 141 consecutive patients accepted for cardiac transplantation. All deaths and 88% of the deteriorations to status 1 on the waiting list occurred in patients with either a CI < 2.0 or a VO2 < 12. In those with a CI < 2.0 and a VO2 < 12, 38% died or deteriorated to status 1 in the first year on the waiting list. Patients with CI > or = 2.0 and a VO2 > or = 12 all survived throughout follow up. Using a Cox's proportional hazards model with CI and peak VO2 as covariates, tables were constructed predicting the chance of surviving for (a) 60 days and (b) 1 year on the waiting list. CONCLUSIONS: These data provide a basis for risk stratification of status 2 patients on the heart transplant waiting list.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Meyer, B., Mortl, D., Strecker, K., Hulsmann, M., Kulemann, V., Neunteufl, T., Pacher, R., Berger, R. (2005). Flow-Mediated Vasodilation Predicts Outcome in Patients With Chronic Heart Failure: Comparison With B-Type Natriuretic Peptide. J Am Coll Cardiol 46: 1011-1018 [Abstract] [Full Text]  
• Menezes Falcao, L., Pinto, F., Ravara, L., van Zwieten, P. A. (2004). BNP and ANP as diagnostic and predictive markers in heart failure with left ventricular systolic dysfunction. Journal of Renin-Angiotensin-Aldosterone System 5: 121-129 [Abstract]  
• Anker, S. D., Doehner, W., Rauchhaus, M., Sharma, R., Francis, D., Knosalla, C., Davos, C. H., Cicoira, M., Shamim, W., Kemp, M., Segal, R., Osterziel, K. J., Leyva, F., Hetzer, R., Ponikowski, P., Coats, A. J.S. (2003). Uric Acid and Survival in Chronic Heart Failure: Validation and Application in Metabolic, Functional, and Hemodynamic Staging. Circulation 107: 1991-1997 [Abstract] [Full Text]  
• Koglin, J.o., Pehlivanli, S., Schwaiblmair, M., Vogeser, M., Cremer, P., vonScheidt, W. (2001). Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 38: 1934-1941 [Abstract] [Full Text]  
• Zugck, C., Kruger, C., Kell, R., Korber, S., Schellberg, D., Kubler, W., Haass, M. (2001). Risk stratification in middle-aged patients with congestive heart failure: prospective comparison of the Heart Failure Survival Score (HFSS) and a simplified two-variable model. Eur J Heart Fail 3: 577-585 [Abstract] [Full Text]